Efficacy of Prednisolone and Mizoribine Therapy for Diffuse IgA Nephropathy

American Journal of Nephrology

Volumn 24, Issue 1, 2004, Pages 147-153

  Kawasaki, Yukihiko ^a,b   Suzuki, Junzo ^a   Sakai, Nobuko ^a   Etoh, Shigehiko ^a   Murai, Hiromitch ^a   Nozawa, Ruriko ^a   Suzuki, Hitoshi ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b NONE   (Japan)

Author keywords

IgA nephropathy; Mizoribine; Prednisolone

Indexed keywords

ALPHA ACTIN; DILAZEP; IMMUNOGLOBULIN A; MIZORIBINE; PREDNISONE; PROTEIN; URIC ACID; WARFARIN;

ACIDEMIA; ADOLESCENT; ARTICLE; CELL INFILTRATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DRUG EFFICACY; EVALUATION; FEMALE; FOLLOW UP; GLAUCOMA; GLOMERULUS; GROWTH RETARDATION; HEMATURIA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; INCIDENCE; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY INTERSTITIUM; LABORATORY TEST; LEUKOPENIA; MACROPHAGE; MALE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; SCHOOL CHILD; SIDE EFFECT; SMOOTH MUSCLE FIBER; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; URINARY EXCRETION;

ANTICOAGULANTS; BIOPSY; CHILD; DILAZEP; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLOMERULONEPHRITIS, IGA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY GLOMERULUS; MALE; PREDNISOLONE; PROSPECTIVE STUDIES; RIBONUCLEOSIDES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VASODILATOR AGENTS; WARFARIN;

EID: 1342301599     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000076243     Document Type: Article

References (30)

1. Berger J, Hinglais N: Les dépôts intercapillaires d'IgA-IgG. J Urol Nephrol 1968;74:694-695.
2. Droz D: Natural history of primary glomerulonephritis with mesangial deposits of IgA. Contrib Nephrol. Basel, Karger, 1976, vol 2, pp 150-157.
3. Chida Y, Tomura S, Takeuchi J: Renal survival rate of IgA nephropathy. Nephron 1985;40:189-194.
4. Hogg RJ, Silvia F, Wyatt R et al: A multicenter study of IgA nephropathy in children: A report of the Southwest Pediatric Nephrology Study Group. Kidney Int 1982;22:643-652.
5. Andreoli SP, Bergstein JM: Treatment of severe IgA nephropathy in children. Pediatr Nephrol 1989;3:248-253.
6. Woo KT, Lee GS, Lim CH et al: Effects of triple therapy in IgA nephritis A follow-up study 5 years later. Clin Nephrol 1991;36:60-66.
7. Welch TR, Fryer C, Quinlan M et al: Double-blind, controlled trial of short-term prednisone therapy in immunoglobulin A glomerulonephritis. J Pediatr 1992;121:474-477.
8. Murakami K, Yoshioka K, Maki S et al: Combined therapy in children and adolescents with IgA nephropathy. Nippon Jinzo Gakkai Shi 1994;36:38-43.
9. Goumenos D, Ahuja M, Shortland JR, Brown CB: Can immunosuppressive drugs slow the progression of IgA nephropathy? Nephrol Dial Transplant 1995;10:1173-1181.
10. Kobayashi Y, Hiki Y, Tateno S et al: Steroid therapy during the early stage of progressive IgA nephropathy: A 10-year follow-up study. Nephron 1996;72:237-242.
11. Yoshikawa N, Ito H, Ninomiya M, for the Japanese pediatric IgA nephropathy treatment study group: A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. J Am Soc Nephrol 1999;10:101-109.
12. Mizuno K, Tsujino M, Atsumi K et al: Studies on Bredinin. I. Isolation, characterization and biological properties. J Antibiot (Tokyo) 1974;27:775-782.
13. Hughes SE, Gruber SA: New immunosuppressive drugs in organ transplantation. J Clin Pharmacol 1996;36:1081-1092.
14. Ishikawa H: Mizoribine and mycophenolate mofetil. Curr Med Chem 1999;6:575-597.
15. Kaneko K, Nagaoka R, Ohtomo Y, Yamashiro Y: Mizoribine for childhood IgA nephropathy. Nephron 1999;83:376-377.
16. Nagaoka R, Kaneko K, Ohtomo Y, Yamashiro Y: Mizoribine treatment for childhood IgA nephropathy. Pediatr Int 2002;44:217-223.
17. Southwest Pediatric Nephrology Study Group: A clinico-pathologic study of crescentic glomerulonephritis in 50 children: A report of the Southwest Pediatric Nephrology Study Group. Kidney Int 1985;27:450-458.
18. National Heart, Lung and Blood Institute, Bethesda, Md: Report of the second task force on blood pressure control in children. Pediatrics 1987;79:1-25.
19. Churg J, Bernstein J, Glassock RJ: Classification and Atlas of Glomerular Diseases, ed 2. Tokyo, Igaku-Shoin, 1995, pp 86-88.
20. Shigematsu H: Histological grading and staging of IgA nephropathy. Pathol Int 1997;47:194-202.
21. Shigematsu H: Multiplicity of histological renal lesions in IgA nephropathy: Retrospective analysis of histologic grade and stage in serial biopsy specimens. Clin Exp Nephrol 1998;2:137-141.
22. Yoshikawa N, Ito H, Nakamura H: Prognostic factors in childhood IgA nephropathy. Nephron 1992;60:60-67.
23. Nagata M, Akioka Y, Ito K et al: Macrophages in childhood IgA nephropathy. Kidney Int 1995;48:527-535.
24. Oberle GP, Thaiss F, Stahl RAK: Increased oxygen radical and eicosanoid formation in glomerular macrophages from rats with immune mediated mesangial cell injury. Kidney Int 1992;74:42-69.
25. Diamond JR, Pesek I; Glomerular tumor necrosis factor and interleukin-1 during acute aminonucleoside nephrosis: An immunohistochemical study. Lab Invest 1991;64:21-28.
26. Sappino AP, Schurch W, Gabbiani G: Differentiation repertoire of fibroblastic cells: Expression of cytoskeletal proteins as marker of phenotypic modulations. Lab Invest 1990;63:144-161.
27. Alpers CE, Hudkins KL, Gown AM, Johnson RJ: Enhanced expression of 'muscle-specific' actin in glomerulonephritis. Kidney Int 1992;41:1134-1142.
28. Waldo FB, Alexander R, Wyatt RJ, Kohaut EC: Alternate-day prednisone therapy in children with IgA-associated nephritis. AJKD 1989;1:55-60.
29. Yoshioka K, Ohashi Y, Sakai T et al: A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome. Kidney Int 2000;58:317-324.
30. Shimizu M, Shou I, Tomino Y et al: Effect of mizoribine on glomerulonephritis of earlystage IgA nephropathy in ddY mice. Nephron 1998;79:67-72.